Abstract
Inhaled nitric oxide (iNO) has been used to treat both term and preterm infants with respiratory failure. Term infants with persistent pulmonary hypertension, either as a primary cause or secondary to other disease processes, respond to iNO with improvement in oxygenation indices and a decreased need for extracorporeal membrane oxygenation. Infants with congenital diaphragmatic hernia are the exception to this finding, with little clinical benefit observed with iNO treatment. Although respiratory disease in preterm infants has a component of increased pulmonary vascular resistance, little benefit of iNO administration has been observed in premature infants either early in their course or later as a treatment to prevent the evolution of chronic lung disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Culotta E, Koshland Jr DE . NO news is good news. Science 1992; 258: 1862–1865.
Martin RJ, Walsh MC . Inhaled nitric oxide for preterm infants—who benefits? N Engl J Med 2005; 353: 82–84.
Finer NN, Barrington KJ . Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006; 18: CD000399.
Barrington KJ, Finer NN . Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2007; 18: CD000509.
Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105: 14–20.
Mugford M, Elbourne D, Field D . Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 2008; 16: CD001340.
Abman SH, Chatfield BA, Hall SL, McMurtry IF . Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990; 259: H1921–H1927.
Fratacci MD, Frostell CG, Chen TY, Wain Jr JC, Robinson DR, Zapol WM . Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75: 990–999.
Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM . Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038–2047.
Zayek M, Cleveland D, Morin III FC . Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide. J Pediatr 1993; 122: 743–750.
Barefield ES, Karke VA, Phillips JB, Carlo WA . Inhaled nitric oxide in term infants with hypoxemic respiratory failure. J Pediatr 1996; 129: 279–286.
Day RW, Lynch JM, White KS, Ward RM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics 1996; 98: 698–705.
Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari EE, Mayock DE et al. Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131: 55–62.
The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597–604.
Roberts Jr JD, Fineman J, Morin III FC, Shaul PW, Rimar S, Schreiber MD et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336: 605–610.
Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1997; 100: E7.
The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997; 99: 838–845.
Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics 1998; 101: 325–334.
Cornfield DN, Maynard RC, deRegnier RA, Guiang III SF, Barbato JE, Milla CE . Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Pediatrics 1999; 104: 1089–1094.
Franco-Belgium collaborative NO trial group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet 1999; 354: 1066–1071.
Clark RH, Keuser TJ, Walker MW, Southgate MS, Huckaby JL, Perez JA et al., for the Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 2000; 342: 469–474.
Christou H, Van Marter LJ, Wessel DL, Allred EN, Kane JW, Thompson JE et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med 2000; 28: 3722–3727.
Sadiq HF, Mantych G, Benawra RS, Devaskar UP, Hocker JR . Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial. J Perinatol 2003; 23: 98–103.
Konduri GG, Solimano A, Sokol GM, Singer J, Ehrenkranz RA, Singhal N et al., Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics 2004; 113: 559–564.
The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the The Neonatal Inhaled Nitric Oxide Study Group (NINOS). J Pediatr 2000; 136: 611–617.
Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT . Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J Pediatr 2002; 140: 306–310.
Suresh GK, Soll RF . Overview of surfactant replacement trials. J Perinatol 2005; 25: S40–S44.
Walther FJ, Benders MJ, Leighton JO . Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992; 90: 899–904.
Kinsella JP, Ivy DD, Abman SH . Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr Res 1994; 36: 402–408.
Skimming JW, DeMarco VG, Cassin S . The effects of nitric oxide inhalation on the pulmonary circulation of preterm lambs. Pediatr Res 1995; 37: 35–40.
Subhedar NV, Ryan SW, Shaw NJ . Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77: F185–F190.
Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S . Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354: 1061–1065.
Srisuparp P, Heitschmidt M, Schreiber MD . Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome. J Med Assoc Thai 2002; 85: S469–S478.
Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P . Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099–2107.
Field D, Elbourne D, Truesdale A, Grieve R, Hardy P, Fenton AC et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial. Pediatrics 2005; 115: 926–936.
Hascoet JM, Fresson J, Claris O, Hamon I, Lombet J, Liska A et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005; 146: 318–323.
Van Meurs KP, Wright L, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353: 13–22.
Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343–353.
Dani C, Bertini G, Pezzati M, Filippi L, Cecchi A, Rubaltelli FF . Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. Acta Paediatrica 2006; 95: 1116–1123.
Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355: 354–364.
Bennett AJ, Shaw NJ, Gregg JE, Subhedar NV . Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide. Acta Paediatrica 2001; 90: 573–576.
Mestan K, Marks J, Hecox K, Huo D, Schreiber MD . Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005; 353: 23–32.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soll, R. Inhaled nitric oxide in the neonate. J Perinatol 29 (Suppl 2), S63–S67 (2009). https://doi.org/10.1038/jp.2009.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2009.40